Literature DB >> 33767454

FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.

Bishal Gyawali1,2, Aaron S Kesselheim3.   

Abstract

Entities:  

Year:  2021        PMID: 33767454     DOI: 10.1038/s41571-021-00504-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

Authors:  Otto Metzger Filho; Daniel G Stover; Sarah Asad; Peter J Ansell; Mark Watson; Sibylle Loibl; Charles E Geyer; Junu Bae; Katharine Collier; Mathew Cherian; Joyce O'Shaughnessy; Michael Untch; Hope S Rugo; Jens B Huober; Mehra Golshan; William M Sikov; Gunter von Minckwitz; Priya Rastogi; David Maag; Norman Wolmark; Carsten Denkert; W Fraser Symmans
Journal:  JAMA Oncol       Date:  2021-04-01       Impact factor: 31.777

  1 in total
  1 in total

1.  Analysis on factors behind sentinel lymph node metastasis in breast cancer by color ultrasonography, molybdenum target, and pathological detection.

Authors:  Aibibai Yiming; Muhetaer Wubulikasimu; Nuermaimaiti Yusuying
Journal:  World J Surg Oncol       Date:  2022-03-08       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.